The FDA approved insulin icodec (Awiqli) as the first once-weekly, long-acting basal insulin for glycemic control in adults ...

The AACE update to its 2026 algorithm for the management of type 2 diabetes includes a new section on diabetes classification ...

The FDA approved a once-weekly, long-acting basal insulin for adults with type 2 diabetes as an alternative to daily basal ...

Night shift workers living with type 2 diabetes (T2D) face challenges in maintaining a healthy diet and managing their condition. The findings by King's College London, as part of a series of studies ...

The risk for dementia is significantly higher in people with diabetes, with the greatest risk among those with type 1 disease ...

Introduction India’s T2D population carries a substantial burden-nearly two-thirds of individuals with T2D are overweight or obese, indicating a significant cardio-metabolic risk burden (1).

Oral semaglutide improved multiple cardiometabolic metrics among adults with type 2 diabetes at high risk for atherosclerotic ...

March 26 (Reuters) - The U.S. Food and Drug Administration has approved Novo Nordisk's insulin injection, Awiqli, to control ...

Some patients with type 2 diabetes will be able to switch from daily insulin injections to this first-of-its-kind once-weekly alternative.

Type 2 diabetes is the most common kind of diabetes. Lifestyle factors such as diet and exercise, genetics, and some medications can cause you to develop the condition. It’s sometimes called ...

Jessica Migala has been a health, fitness, and nutrition writer for almost 15 years. She has contributed to more than 40 print and digital publications, including Health and Runner's World. Jessica ...